Stockscreener 앱 받기
4.64
0.29%
-0.02
전일 마감가:
$4.66
열려 있는:
$4.66
하루 거래량:
1.01M
Relative Volume:
0.50
시가총액:
$780.84M
수익:
$25.55M
순이익/손실:
$-341.97M
주가수익비율:
-1.7249
EPS:
-2.69
순현금흐름:
$-304.44M
1주 성능:
-17.03%
1개월 성능:
-27.74%
6개월 성능:
-38.54%
1년 성능:
-41.63%
1일 변동 폭
$4.48
$4.76
1주일 범위
$4.48
$5.63
52주 변동 폭
$4.48
$12.14
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
399 BINNEY STREET, CAMBRIDGE
RLAY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RLAY | 4.645 | 780.84M | 25.55M | -341.97M | -304.44M | -2.69 |
| VRTX | 450.60 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.31 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.22 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.28 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.27 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround - Yahoo Finance
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround - Yahoo Finance
First Turn Management LLC Buys New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% – Here’s What Happened - Defense World
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
(RLAY) Trading Report - Stock Traders Daily
Relay Therapeutics stock hits 52-week low at $5.59 - Investing.com India
Relay Therapeutics stock hits 52-week low at $5.59 By Investing.com - Investing.com UK
Analyzing Valneva (NASDAQ:VALN) and Relay Therapeutics (NASDAQ:RLAY) - Defense World
NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World
Relay Therapeutics' SWOT analysis: PI3K inhibitor progress fuels stock potential - Investing.com
HC Wainwright Forecasts Strong Price Appreciation for Relay Therapeutics (NASDAQ:RLAY) Stock - Defense World
Research Analysts Offer Predictions for RLAY FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World
Relay Therapeutics (NASDAQ:RLAY) Given New $20.00 Price Target at HC Wainwright - MarketBeat
Relay Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Relay Therapeutics Reports Q3 2024 Results and Advances - TipRanks
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times
Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Where are the Opportunities in (RLAY) - Stock Traders Daily
Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts - Investing.com Australia
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts By Investing.com - Investing.com South Africa
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - The Manila Times
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, - EIN News
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Several Relay Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com Canada
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase By Investing.com - Investing.com South Africa
Financial Snapshot: Analyzing Relay Therapeutics Inc (RLAY)’s Key Ratio Metrics - The Dwinnex
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
How did Relay Therapeutics Inc (RLAY) fare last session? - US Post News
Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC Wainwright - MarketBeat
Relay Therapeutics stock holds price target on FDA approval By Investing.com - Investing.com UK
Relay Therapeutics Inc (RLAY) receives a Buy rating from Jefferies - Knox Daily
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
릴레이 테라퓨틱스 주식 (RLAY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Catinazzo Thomas | Chief Financial Officer |
Oct 28 '24 |
Sale |
6.06 |
6,802 |
41,220 |
306,391 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 29 '24 |
Sale |
5.95 |
2,300 |
13,685 |
304,091 |
| Bergstrom Donald A | President, R&D |
Oct 28 '24 |
Sale |
6.06 |
2,688 |
16,289 |
520,745 |
| Adams Brian | Chief Legal Officer |
Oct 28 '24 |
Sale |
6.06 |
1,632 |
9,890 |
321,907 |
1.80%
0.42%
자본화:
|
볼륨(24시간):